Gordon Naylor, who stepped into the interim chief executive role in February, has completed a 90-day review and set out a plan to accelerate the company’s transformation. …
CSL signals course correction as interim CEO outlines revised outlook and major impairments
May 11, 2026 Latest NewsBioPharmaAustralian BiotechNews of the Day
Latest Video
New Stories
-
US launches investigation into pharmaceutical pricing with potential broad implications
June 23, 2026 - - Latest News -
Access delays in cancer medicines are costing Australia productivity, livelihoods, and lives
June 23, 2026 - - Latest News -
If we're incapable of delivering meaningful change, we should hope the US intervenes
June 23, 2026 - - Latest News -
'AUScelerate' emerges as new name for MTPConnect ahead of BIO 2026
June 22, 2026 - - Australian Biotech -
CSL executive Elizabeth Rex joins AusBiotech board as observer
June 22, 2026 - - Latest News -
It seems that one critical stakeholder group is missing in this website design
June 22, 2026 - - Latest News -
May 2026 delivers paediatric dosing flexibility, vaccine decisions, and policy updates
June 22, 2026 - - Latest News